Asset Details
Do you wish to reserve the book?
Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia
Do you wish to request the book?
Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia
2017
Overview
The endocannabinoid system (ECS) is a group of neuromodulatory lipids, enzymes, and receptors involved in numerous behavioral and physiological processes such as mood, memory, and appetite. Recently, longitudinal and postmortem studies have shown that the ECS might be involved in neuropsychiatric disorders like schizophrenia. However, despite the large amount of research, our knowledge of the ECS and its implication in this debilitating disorder is still largely limited. This review aims at providing a comprehensive overview of the current state of knowledge of the ECS in schizophrenia and presenting some potential antipsychotic compounds that modulate this system. Findings from animal and human studies, and their implications for pharmacotherapy, will be integrated and discussed in this paper. A closer look will be given at the roles of the cannabinoid receptors type 1 (CB
1
) and type 2 (CB
2
), as well as the endogenous ligand
N
-arachidonoylethanolamine (AEA) and 2-arachidonylglycerol (2-AG), in the development of psychotic and schizophrenia-like symptoms.
Publisher
Springer US,Springer Nature B.V
Subject
/ Antipsychotic Agents - pharmacology
/ Antipsychotic Agents - therapeutic use
/ Biomedical and Life Sciences
/ Cannabinoid Receptor Modulators - pharmacology
/ Cannabinoid Receptor Modulators - therapeutic use
/ Endocannabinoids - antagonists & inhibitors
/ Endocannabinoids - pharmacology
/ Endocannabinoids - physiology
/ Endocannabinoids - therapeutic use
/ Humans
/ Receptor, Cannabinoid, CB1 - agonists
/ Receptor, Cannabinoid, CB1 - antagonists & inhibitors
/ Receptor, Cannabinoid, CB1 - physiology
/ Receptor, Cannabinoid, CB2 - agonists
/ Receptor, Cannabinoid, CB2 - antagonists & inhibitors
/ Receptor, Cannabinoid, CB2 - physiology
We currently cannot retrieve any items related to this title. Kindly check back at a later time.